NCT01532102View on ClinicalTrials.gov

Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 28, 2012

Primary Completion Date

May 6, 2013

Study Completion Date

May 6, 2013

Conditions
Anogenital WartsCondylomata AcuminataHuman Papillomavirus Infection
Interventions
DRUG

AP611074

DRUG

Placebo

Placebo gel manufactured to appear identical to AP611074 5% gel

Trial Locations (4)

75014

SGS Aster, Paris

94010

Hopital Henri Mondor-Dept of Dermatology, Créteil

C1122AAL

IADT - Instituto Argentino de Diagnostico y Tratamiento S.A., Buenos Aires

C1181ACH

Hospotal Italinao de Buenos Aires - Dept of Dermatology and Gynecology, Buenos Aires

Sponsors

Lead Sponsor

Anaconda Pharma
All Listed Sponsors
lead

Anaconda Pharma

INDUSTRY

NCT01532102 - Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts | Biotech Hunter | Biotech Hunter